Subscribe To
Kapruvia® (difelikefalin) recommended by england’s nice for the treatment of adults with moderate-to-severe ckd-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chro...
May 18, 2023, 6:00 am
Cara therapeutics announces results from the komfort phase 2 trial of oral difelikefalin for the treatment of pruritus in notalgia paresthetica published in the new england journal of medicine
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment STAMFORD, Conn., Feb. 08...
February 8, 2023, 10:00 pm
Cara therapeutics: all eyes on korsuva launch metrics
Korsuva has been approved in an indication for which, it faces little in the way of competition. A number of expansion opportunities await oral ...
September 1, 2022, 5:03 pm